Igor Mochalkin

Igor Mochalkin has had a diverse work experience in the field of computational chemistry. Igor most recently served as the Director of Computational Chemistry at Vividion Therapeutics. Inc. since August 2022. Prior to that, they were the Director, Head of Computational Chemistry at Zentalis Pharmaceuticals from April 2021 to June 2022. Igor also worked as a Director at Vertex Pharmaceuticals from April 2019 to April 2021 and as an Associate Director at EMD Serono, Inc. from May 2016 to March 2019. Before that, they served as a Principal Scientist at Eli Lilly and Company from June 2012 to April 2016. Igor has a proven track record as a Senior Principal Research Investigator at EMD Serono, Inc. from July 2009 to June 2012, a Principal Scientist at Pfizer Global Research & Development from November 2003 to February 2009, and a Product Manager at Accelrys from October 2000 to October 2003. Igor started their career as a Post-doctoral Research Assistant at the University of California San Diego from September 1999 to July 2000.

Igor Mochalkin obtained a PhD in Chemistry from Michigan State University from 1995 to 1999. Prior to that, they earned a Diploma in Chemistry from Lomonosov Moscow State University (MSU) between 1989 and 1994. Additionally, they hold a Project Management Professional (PMP) certification from the Project Management Institute.